![]() Nodus Oncology is a biotech company developing first and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Mary-Jane Elliott, Lindsey Neville, Davide Nodus Oncology ”įor more information about Nodus Oncology, please contact: ”īert Klebl, CEO of LDC said : “ We are delighted to see our collaboration with Cumulus Oncology evolve into a partnership with Nodus Oncology and look forward to supporting Ian and the team at Nodus to expand the company’s DDR pipeline by leveraging LDC’s expertise in drug discovery. Ian brings with him a wealth of experience from the biopharmaceutical industry focused on the DDR field and h is experience leading successful drug discovery and development activities will be invaluable as we continue to develop Nodus’ DDR inhibitor pipeline. ![]() With more than 30 years’ experience in leading successful R&D programmes as well as extensive and in-depth oncology expertise, including in the DDR field, Ian brings the expertise needed to develop and deliver Nodus’ pipeline successfully.Ĭlare Wareing, CEO of Cumulus Oncology says “ I am delighted to welcome Ian as Nodus Oncology’s CEO. Nodus is led by Chief Executive Officer Dr Ian Waddell PhD, Chief Scientific Officer of Cumulus Oncology. The financing will be used to expand and develop Nodus’ portfolio of first-in-class and best in class assets. Newly appointed CEO, Ian Waddell PhD, will lead the discovery and preclinical development of Nodus On cology’s DDR-focused pipeline and will be supported by a team including Luis Toledo, PhD, Scientific Founder and A dvisorĮdinburgh, Scotland, 6 September 2022 – Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, today launches with seed funding from Cumulus Oncology, a Scottish biotech creation studio, and announces a partnership with the Lead Discovery Center (LDC) in Dortmund (Germany). ![]() N odus Oncology l aunches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |